These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19524492)

  • 1. [Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain].
    Figueras-Aloy J; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    An Pediatr (Barc); 2009 Jul; 71(1):47-53. PubMed ID: 19524492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age.
    Stensballe LG; Fullarton JR; Carbonell-Estrany X; Simões EA
    Pediatr Infect Dis J; 2010 Apr; 29(4):374-6. PubMed ID: 20016397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age.
    Doering G; Gusenleitner W; Belohradsky BH; Burdach S; Resch B; Liese JG
    Pediatr Infect Dis J; 2006 Dec; 25(12):1188-90. PubMed ID: 17133170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.
    Sampalis JS; Langley J; Carbonell-Estrany X; Paes B; O'Brien K; Allen U; Mitchell I; Aloy JF; Pedraz C; Michaliszyn AF
    Med Decis Making; 2008; 28(4):471-80. PubMed ID: 18556643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].
    Figueras Aloy J; Carbonell Estrany X;
    An Pediatr (Barc); 2010 Aug; 73(2):98.e1-4. PubMed ID: 20621574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
    Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
    Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule.
    Rietveld E; Vergouwe Y; Steyerberg EW; Huysman MW; de Groot R; Moll HA;
    Pediatr Infect Dis J; 2006 Mar; 25(3):201-7. PubMed ID: 16511380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Perinatal history and hospitalization for bronchiolitis. A comparison with the impact-RSV Study Group].
    Bonillo Perales A ; DíezDelgado Rubio J ; Ortega Montes A ; Infante Márquez P ; Jiménez Liria M ; Batlles Garrido J ; López Muñoz J
    An Esp Pediatr; 2000 Dec; 53(6):527-32. PubMed ID: 11148149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
    Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
    Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
    Klimek M; Kwinta P; Kruczek P; Pietrzyk JJ
    Przegl Lek; 2009; 66(1-2):34-8. PubMed ID: 19485253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.
    Simões EA; Carbonell-Estrany X; Fullarton JR; Rossi GA; Barberi I; Lanari M;
    J Matern Fetal Neonatal Med; 2011 Jan; 24(1):152-7. PubMed ID: 20486882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.
    Park HW; Lee BS; Kim AR; Yoon HS; Kim BI; Song ES; Kim WT; Lim J; Kim S; Jin HS; Byun S; Chee DH; Kim KS
    Pediatr Infect Dis J; 2012 Aug; 31(8):e99-104. PubMed ID: 22531234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.